公司资料
Embecta 股价、新闻与催化剂
- 股票代码:
- EMBC
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
5.13 USD (+0.59%)
收盘价
最后更新: 2026年8月17日
207M USD
市值
股价为何变动
As of Aug 17, 2026, EMBC closed up 0.59% at $5.13. No new same-company headline was identified in the current news window.
公司概览
Global Diabetes Care
Embecta is a global diabetes-care company built on a nearly century-long history in insulin delivery. Its products are used by people who self-administer injectable therapies and by healthcare systems supporting diabetes management.
Injection-Device Portfolio
The company's core portfolio includes pen needles and syringes, with market-specific products moving through U.S. and European regulatory review. These high-volume consumables serve both branded diabetes therapies and a growing market for injectable GLP-1 medicines.
Owen Mumford Expansion
The acquisition of Owen Mumford broadens Embecta's drug-delivery capabilities and product range. The company also works with pharmaceutical partners to co-package its pen needles with generic GLP-1 therapies in multiple international markets.
未来催化剂
- Regulatory outcomes for market-appropriate pen needles under review by the FDA and for CE Mark certification.
- Market-appropriate syringe launches in selected geographies in the coming months.
- U.S. launch of a GLP-1 small-pack format in the fourth quarter of fiscal 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。